Healthcare Glob. ENT. Ltd
NSE: HCG · Hospital · sector
₹569.85NSE close 2026-10-26
Key numbers
Market cap₹8,508 cr
Price₹569.85
52w high / low₹805 / ₹513
P/E367.6xSector median 42.5x
P/B6.4xSector median 4.9x
Book value₹89.2
Dividend yield–Sector median 0.17%
ROE2.0%Sector median 12.1%
ROCE9.3%Sector median 13.8%
OPM16.6%Sector median 20.3%
Debt / equity0.68xSector median 0.24x
EV/EBITDA20.4xSector median 23.6x
Interest cover1.2x
Current ratio1.09x
Sales growth 3y+14.5%Sector median +14.1%
Profit growth 3y-22.3%Sector median +14.7%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 32 companies in Hospital (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹541 cr vs borrowings ₹910 cr (FY26): borrowings are higher by ₹369 cr.
- Operating profit covered interest 1.2x in the last 12 months.
- 5.17% of the promoters' shares are pledged (3.3% of all shares).
- Operating cash flow was below net profit in 0 of the last 5 years.
- Net loss in 1 of the last 8 quarters.
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 133% of net profit in the last 12 months.
- No dividend in the last 5 financial years.
- Price ₹569.85 on 2026-10-26: -29.2% from the 52-week high, +11.0% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹752.90 · low ₹412.70
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 554 | 558 | 585 | 613 | 647 | 633 | 652 | 695 |
| EBITDA | 102 | 87 | 106 | 108 | 123 | 97 | 93 | 122 |
| OPM % | 18.5% | 15.7% | 18.1% | 17.6% | 19.1% | 15.3% | 14.3% | 17.6% |
| Other income | 11 | 6 | 10 | 7 | 3 | 2 | 13 | 12 |
| Net profit | 18 | 7 | 7 | 5 | 16 | -9 | 2 | 14 |
| EPS (₹) | 1.29 | 0.50 | 0.53 | 0.34 | 1.16 | -0.68 | 0.15 | 0.92 |
| Revenue YoY | +16.9% | +13.5% | +11.5% | +13.4% | ||||
| Profit YoY | -9.6% | -235.1% | -70.5% | +189.9% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 1,398 | 1,694 | 1,912 | 2,223 | 2,545 | 2,627 |
| EBITDA | 333 | 299 | 333 | 387 | 421 | 436 |
| Net profit | 54 | 29 | 48 | 44 | 14 | 23 |
| EPS (₹) | 4.14 | 2.11 | 3.46 | 3.19 | 0.97 | 1.55 |
| Revenue growth | +21.2% | +12.8% | +16.3% | +14.5% | +13.8% | |
| Profit growth | -45.4% | +64.1% | -7.7% | -69.0% | -38.6% | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +14.5% | +20.2% | +13.8% |
| Net profit | -22.3% | – | -38.6% |
| EPS | -22.8% | – | – |
| Share price | – | +13.5% (2y) | -23.7% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 861 | 826 | 922 | 1,332 |
| Borrowings | – | 399 | 673 | 1,002 | 910 |
| Cash & equivalents | – | 197 | 303 | 348 | 541 |
| Total assets | – | 2,316 | 2,708 | 3,543 | 3,923 |
| Fixed assets | – | 1,353 | 1,505 | 1,963 | 2,041 |
| Capital work in progress | – | 18 | 83 | 25 | 19 |
| Investments | – | 7 | 7 | 7 | 7 |
| Receivables | – | 303 | 294 | 401 | 421 |
| Inventory | – | 38 | 43 | 53 | 60 |
| Payables | – | 248 | 281 | 334 | 351 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 220 | 252 | 285 | 317 | 347 |
| Cash from investing | 125 | -133 | -226 | -488 | -177 |
| Cash from financing | -155 | -140 | -64 | -42 | 241 |
| Capex | 71 | 133 | 186 | 209 | 292 |
| Free cash flow | 149 | 118 | 99 | 108 | 55 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 3.4% | 5.8% | 4.8% | 1.0% |
| ROCE % | – | 11.8% | 11.7% | 10.9% | 9.0% |
| Debtor days | – | 65 | 56 | 66 | 60 |
| Inventory days | – | 33 | 33 | 33 | 32 |
| Payable days | – | 214 | 216 | 210 | 185 |
| Cash conversion cycle (days) | – | -116 | -127 | -111 | -93 |
| Working capital days | – | 2 | -12 | -33 | 12 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 64.21% |
| FIIs | 2.69% |
| DIIs | 20.77% |
| of which Mutual funds | 18.73% |
| of which Insurance | 0.89% |
| Government | 0.00% |
| Public (non-institutions) | 12.32% |
| Quarter | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 71.22% | 62.46% | 63.78% | 63.77% | 64.21% | 64.21% | 64.21% | 64.21% |
| Promoter group | % |
|---|---|
| Hector Asia Holdings II PTE. Ltd. | 54.27% |
| B S Ajaikumar | 9.30% |
| Aagnika Ajaikumar | 0.23% |
| Asmitha Ajaikumar | 0.23% |
| Catalyst Trusteeship Limited | 0.18% |
| Anjali Ajaikumar Rossi | 0.00% |
| Bhagya A Ajaikumar | 0.00% |
| Public holders above 1% | % |
|---|---|
| Nippon Life India Trustee Ltd-a/c Nippon India ELS | 5.88% |
| Axis Mutual Fund Trustee Limited A/C Axis Mutual Fund | 4.27% |
| Tata Mutual Fund - Tata Elss -TAX Saver Fund | 4.13% |
| Franklin India Small CAP Fund | 1.57% |
| SBI Healthcare Opportunities Fund | 1.00% |
44,774 shareholders. Pledged: 5.17% of promoter shares.
Peers in Hospital
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| APOLLOHOSP | ₹1,12,797 cr | 54.0x | 11.9x | 23.6% | 21.8% | 15.1% | +14.9% | 0.26% |
| MAXHEALTH | ₹81,266 cr | 55.7x | 7.6x | 14.5% | 13.8% | 26.1% | +22.4% | 0.18% |
| MANIPALHOS | ₹73,581 cr | – | – | – | – | – | – | – |
| FORTIS | ₹55,467 cr | 52.9x | 5.6x | 11.1% | 13.2% | 22.2% | +13.2% | 0.14% |
| NH | ₹33,971 cr | 41.4x | 7.5x | 20.0% | 13.7% | 18.7% | +20.4% | 0.26% |
| ASTERDM | ₹33,523 cr | 104.7x | 7.3x | 8.0% | 12.8% | 16.7% | -27.0% | 0.16% |
| MEDANTA | ₹32,575 cr | 58.5x | 8.2x | 15.1% | 15.8% | 20.5% | +17.9% | 0.04% |
| KIMS | ₹28,123 cr | 131.3x | 12.5x | 9.3% | 9.6% | 19.5% | +21.1% | 0.74% |
| AGARWALEYE | ₹15,065 cr | 101.3x | 7.4x | 7.6% | 16.5% | 27.8% | – | 0.01% |
| HCG | ₹8,508 cr | 367.6x | 6.4x | 2.0% | 9.3% | 16.6% | +14.5% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-03-02 | Rights | Rights 1:17 @ Premium Rs 502/- |
| 2022-09-22 | Other | Annual General Meeting |
| 2021-09-23 | Other | Annual General Meeting |
| 2019-09-19 | Other | Annual General Meeting |
| 2018-09-19 | Other | Annual General Meeting |
| 2017-08-03 | Other | Annual General Meeting |
| 2016-09-22 | Other | Annual General Meeting |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Medical and Healthcare: Medical and Healthcare
| Sector | Healthcare |
| Industry | Hospital |
| Sub-industry | Hospital |
| Symbol | HCG |
| BSE code | 539787 |
| ISIN | INE075I01017 |
| Face value | ₹10.0 |
| Incorporated | 1998-03-12 |
| Website | www.hcgoncology.com |
| Plants (India / abroad) | 44 / 1 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.